BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Shares of Biohaven Ltd. (NYSE: BHVN) were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease.
Currently, there are no FDA-approved therapy for the given indication.
The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) following three years of treatment.
Year to date, shares of Biohaven have gained 7.4% with no change for the industry.
Image Source: Zacks Investment Research
BHVN’s Pivotal BHV4157-206-RWE Study Data
The study met the primary endpoint on the change from baseline in the f-SARA at three years in all study population genotypes following treatment with troriluzole (200 mg) in SCA patients.
Also, treatment with troriluzole led to statistically significant improvements in the f-SARA at years one and two. Data collected from multiple analyses showed a robust and clinically meaningful slowing of disease progression in SCA patients.
Importantly, treatment with troriluzole slowed disease progression by 50% to …
Full story available on Benzinga.com
